Cryoport, Inc. announced that it will be providing its advanced cryogenic logistics solutions to support ProMab Biotechnologies' ("ProMab") new chimeric-antigen receptors (CARs), and specifically CAR-redirected T-cells (CAR-T). ProMab is leveraging its extensive experience in monoclonal antibody development and immunotherapies to generate CAR-T cells for use in research and preclinical studies, as contracted, and as a proprietary clinical tool. With development activities and manufacturing housed both in the United States and China, ProMab will employ Cryoport's cryogenic logistics solutions for the movement of biologic materials throughout China. ProMab has also expressed interest in leveraging Cryoport's expertise for market expansion in Europe, Canada, and Israel. As ProMab builds-out the new CAR-T cell-engineering segment of its business at its manufacturing facility in China, Cryoport's depot in Singapore will support the transport of these products across China and around the world.